The widespread adoption of appetite-suppressing medications such as Ozempic and Wegovy is driving significant economic transformations well beyond the pharmaceutical sector. Originally formulated to manage type 2 diabetes, these GLP-1 treatments delay gastric emptying and modulate neural hunger pathways, making them powerful tools for weight management. Naturally, the food and hospitality industries were among the first to feel this shift, with restaurants, bars, and bistros adjusting to altered consumer habits. Now, new data from Priceline reveals that the hotel sector is also experiencing a profound operational evolution.

According to the Priceline Travel Trends Report 2027, consumer interest in incorporating GLP-1 regimens into holiday planning is surging. While 85% of individuals on these medications report that the drugs fundamentally alter their vacation behavior, a mere 55% feel current hotel offerings adequately meet their needs. As prescription numbers climb, bridging this gap has become an industry imperative.

For travelers utilizing GLP-1 treatments, essential features include in-room refrigeration for medication pens, protein-focused dining choices, and strength-training fitness facilities. Research shows that 74% of these consumers would actively favor a GLP-1-accommodating property, and 28% are willing to pay a premium for it—opting for early morning meditation over late-night room service, or swapping a pub crawl for a soothing hot stone massage.

GLP-1 Users Are A Growing Audience

Gallup statistics highlighted by Fast Company indicate that roughly 11% of American adults utilized GLP-1 drugs for weight loss in 2026. This translates to approximately 37 million individuals, marking a massive increase from the 10 million reported in 2024.

By comparison, polling from the Kaiser Family Foundation cited by USA Today suggests that nearly one in eight Americans take GLP-1 medications for various health reasons.

In the United Kingdom, NielsenIQ data reveals slightly lower yet substantial metrics: 5% of British adults currently take weight-loss medications, 9% have used them over the past year, and another 5% have prior experience, meaning one in five citizens has engaged with GLP-1s.

British consumers on these drugs typically skew older and frequently patronize dining and drinking establishments. Surveys indicate that roughly a quarter of these users order healthier dishes, select smaller portions, skip starters, and bypass ultra-processed items. Coffee shops have weathered the shift better than fast-food venues and food-serving pubs.

During a Forbes Travel Guide Summit panel, PwC consumer markets leader Ali Furman noted that 20% of all U.S. households now house at least one GLP-1 user, a sharp jump from just 9% a year prior. This acceleration is largely fueled by greater drug affordability and the introduction of oral pill variants.

Furman further noted that institutional projections estimate between 50% and 75% of the adult population could eventually adopt these medications, forecasting immense ramifications for the broader travel economy.

GLP-1 Impact On The Tourist Industry

A growing body of data highlights how GLP-1 users are shifting their leisure preferences:

  • PwC’s 2024 GLP-1 Trends & Impact Survey of roughly 3,000 consumers revealed that users heavily favor health, wellness, and active tourism over food-and-drink-centric itineraries.
  • The same study found that respondents spent 11% less on dining and reduced or entirely cut out alcohol consumption.
  • Research from Michigan State University estimated that if average passenger weights dropped by 10%, commercial airline fuel consumption could decrease by up to 2%, slashing fuel costs by 1.5%.
  • Similarly, Jefferies Research Services projections cited by U.S. News estimate that major airlines like American, Delta, Southwest, and United could collectively save $580 million under comparable weight-reduction models.
  • As reported by NBC News and USA Today, food establishments and hospitality providers are quietly updating their offerings to feature smaller plates, half-portions, high-protein selections, and low-alcohol beverages to accommodate decreased appetites and heightened alcohol sensitivities.

Combined with Priceline's insights, these trends indicate potential headwinds for culinary destinations, all-inclusive resorts, cruise lines, and wine tourism regions.

GLP-1 Impact On The Cruise Industry Is Currently More Anecdotal

While hard data quantifying the exact financial toll of GLP-1 usage on cruise operations remains scarce, the potential disruption is clear. The core demographic for cruises—adults aged 45 to 65—overlaps heavily with the primary audience for weight-loss medications.

Passenger forums and online discussions already highlight traveler anxieties regarding onboard medication management, including the safe storage and disposal of injection pens while at sea.

Shifting attitudes toward onboard dining and drinking present a distinct economic challenge. With cruise revenue heavily reliant on lucrative beverage packages—which often range from $55 to $120 per person daily—reduced alcohol intake by GLP-1 users could significantly impact profit margins, especially as the Cruise Lines International Association reported a record 37.3 million global passengers in 2025.

Ultimately, the evidence underscores that GLP-1 travel is evolving from a niche consideration into a mainstream market force. As properties, eateries, and cruise operators adapt to changing expectations around nutrition, fitness, and medical storage, wellness-driven tourism is rapidly transitioning from a hospitality trend into a core booking driver.